Mar
29
2022
On demand

A scalable lentiviral vector production system based on stable producer cell lines

Sponsor
A scalable lentiviral vector production system based on stable producer cell lines

Currently, the manufacture of clinical-grade LVV is still based on transient transfection of plasmids to 293T cells which caused lots of challenges. EurekaBio has developed the EuLV system, a scalable lentiviral vector production system based on stable producer cell lines. This stable producer cell line no longer requires transient plasmid transfection; instead, all the required packaging genes (such as VSV-G, rev, gag/pol), as well as the customized therapeutic genes or commonly called gene of interest GOI, are stably inserted into the genome of the producer cell lines, and the production of lentivirus is simply achieved by chemical induction. This system is adapted to high cell density suspension culture in the chemically defined medium. EuLV increases the expressing efficiency, improves the product quality and decreases the manufacturing cost.

  • Difference between manufacture LVV using stable producer cell line and transient transfection
  • Key data involved in packaging and producer cell line development
  • 25L scale suspension manufacture process
  • EuLV system's performance based on different GOI

Roy Bin Liu

Business Development Director, EurekaBio

Mr Liu graduated from the Hong Kong University of Science and Technology with a Master degree in Biotechnology. He previously worked in Bio-techne and InvivoGen. Mr Liu joined Eureka Bio in 2016 as COO, and he has extensive knowledge in Gene and Cell therapy industry, and is experienced in business development, project management, process development, cGMP etc.

SPEAKERS

Roy Bin Liu
Roy Bin Liu
Business Development Director at Eureka Bio

You might also like